全文获取类型
收费全文 | 2553462篇 |
免费 | 217496篇 |
国内免费 | 18718篇 |
专业分类
耳鼻咽喉 | 35962篇 |
儿科学 | 74468篇 |
妇产科学 | 65638篇 |
基础医学 | 355769篇 |
口腔科学 | 70788篇 |
临床医学 | 242148篇 |
内科学 | 491526篇 |
皮肤病学 | 49831篇 |
神经病学 | 210183篇 |
特种医学 | 103398篇 |
外国民族医学 | 1024篇 |
外科学 | 378418篇 |
综合类 | 90320篇 |
现状与发展 | 56篇 |
一般理论 | 996篇 |
预防医学 | 200883篇 |
眼科学 | 61552篇 |
药学 | 197921篇 |
192篇 | |
中国医学 | 16429篇 |
肿瘤学 | 142174篇 |
出版年
2021年 | 24298篇 |
2019年 | 24424篇 |
2018年 | 31772篇 |
2017年 | 25489篇 |
2016年 | 26850篇 |
2015年 | 33034篇 |
2014年 | 45474篇 |
2013年 | 60901篇 |
2012年 | 83766篇 |
2011年 | 89218篇 |
2010年 | 52481篇 |
2009年 | 48583篇 |
2008年 | 79143篇 |
2007年 | 83361篇 |
2006年 | 84485篇 |
2005年 | 82746篇 |
2004年 | 75783篇 |
2003年 | 73013篇 |
2002年 | 71173篇 |
2001年 | 116017篇 |
2000年 | 120423篇 |
1999年 | 102445篇 |
1998年 | 29317篇 |
1997年 | 26969篇 |
1996年 | 26368篇 |
1995年 | 26938篇 |
1994年 | 25068篇 |
1993年 | 22710篇 |
1992年 | 80766篇 |
1991年 | 77676篇 |
1990年 | 74561篇 |
1989年 | 71649篇 |
1988年 | 66556篇 |
1987年 | 65398篇 |
1986年 | 61822篇 |
1985年 | 58766篇 |
1984年 | 44389篇 |
1983年 | 37714篇 |
1982年 | 22901篇 |
1979年 | 41310篇 |
1978年 | 28932篇 |
1977年 | 24282篇 |
1976年 | 22774篇 |
1975年 | 23941篇 |
1974年 | 29624篇 |
1973年 | 28045篇 |
1972年 | 26236篇 |
1971年 | 24157篇 |
1970年 | 22740篇 |
1969年 | 21077篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
81.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
82.
Michala G. Rolver Lya K. K. Holland Muthulakshmi Ponniah Nanditha S. Prasad Jiayi Yao Julie Schnipper Signe Kramer Line Elingaard-Larsen Elena Pedraz-Cuesta Bin Liu Luis A. Pardo Kenji Maeda Albin Sandelin Stine Falsig Pedersen 《International journal of cancer. Journal international du cancer》2023,152(8):1668-1684
The mechanisms linking tumor microenvironment acidosis to disease progression are not understood. Here, we used mammary, pancreatic, and colon cancer cells to show that adaptation to growth at an extracellular pH (pHe) mimicking acidic tumor niches is associated with upregulated net acid extrusion capacity and elevated intracellular pH at physiological pHe, but not at acidic pHe. Using metabolic profiling, shotgun lipidomics, imaging and biochemical analyses, we show that the acid adaptation-induced phenotype is characterized by a shift toward oxidative metabolism, increased lipid droplet-, triacylglycerol-, peroxisome content and mitochondrial hyperfusion. Peroxisome proliferator-activated receptor-α (PPARA, PPARα) expression and activity are upregulated, at least in part by increased fatty acid uptake. PPARα upregulates genes driving increased mitochondrial and peroxisomal mass and β-oxidation capacity, including mitochondrial lipid import proteins CPT1A, CPT2 and SLC25A20, electron transport chain components, peroxisomal proteins PEX11A and ACOX1, and thioredoxin-interacting protein (TXNIP), a negative regulator of glycolysis. This endows acid-adapted cancer cells with increased capacity for utilizing fatty acids for metabolic needs, while limiting glycolysis. As a consequence, the acid-adapted cells exhibit increased sensitivity to PPARα inhibition. We conclude that PPARα is a key upstream regulator of metabolic changes favoring cancer cell survival in acidic tumor niches. 相似文献
83.
84.
Melanie Y. T. Chan Arbab Anwar William J. S. Lockley 《Journal of labelled compounds & radiopharmaceuticals》2022,65(4):101-111
Base catalysed exchange with sodium hydroxide, calcium oxide or N,N,N,N-tetramethylguanidine in deuterium oxide is a viable procedure for the preparation of terminally deuterated alkynes for those alkynes stable to strong base. The use of silver perchlorate as a catalyst is an alternative practical option when labelling alkynes which are sensitive to base or contain functionalities which would lead to labelling elsewhere in the molecule. Labelling with this catalyst takes place smoothly at ambient temperature in a mixture of N,N-dimethylformamide and deuterium oxide. 相似文献
85.
86.
87.
88.
89.
目的探讨一次性切口保护套在后腹腔镜肾根治性切除术中的应用及标本取出效率。方法回顾性分析本院2018年12月至2019年6月接受后腹腔镜肾根治性切除术的37例肾癌患者的临床资料。根据手术后标本取出体外的方法分为观察组(18例)和对照组(19例),观察组使用一次性切口保护套,对照组则使用传统自制标本袋;观察比较两组患者标本的取出时间和置入次数等指标。结果观察组与对照组的标本取出时间分别为(225.94±47.04)、(508.84±45.81)s,差异有统计学意义(P<0.05)。观察组中有17例患者标本一次性顺利取出,1例因肿瘤较大,取出困难,经延长切口后顺利取出,所有标本完整均未破裂;对照组中有17例患者标本一次性顺利取出,另外2例患者经适当延长切口后取出,所有标本完整均未破裂。两组置入次数比较,差异无统计学意义(P>0.05)。术后随访1年发现,所有患者均未出现癌细胞经手术切口种植转移的情况。结论在后腹腔镜肾根治性切除术中运用一次性切口保护套来辅助取标本,其手术时间短、操作简单,易上手,具有实用价值,值得临床推广应用。 相似文献
90.
Keith B. Diamond Ivan J. Golub Asad M. Ashraf Samuel J. Swiggett Paul V. Romeo Jack Choueka 《Seminars in Arthroplasty》2022,32(1):15-22
BackgroundWhile studies have demonstrated favorable outcomes in utilization of primary total shoulder arthroplasty (TSA) for the treatment of glenohumeral osteoarthritis (OA), adverse events such as infections can still occur. Periprosthetic joint infections (PJIs) are associated with worse outcomes and patient morbidity. The purpose of this study was to: (1) compare patient demographics amongst TSA patients with and without PJIs following primary TSA; and (2) identify patient-related risk factors for PJIs following primary TSA.MethodsPatients undergoing primary TSA for the treatment of glenohumeral OA were identified using the Mariner administrative claims database by CPT code 23,472. Laterality modifiers were utilized to ensure PJIs were developing in the correct laterality as those patients undergoing primary TSA. Inclusion for the study group consisted of patients who developed PJIs within 2-years after the index procedure, whereas patients who did not develop PJIs served as the comparison cohort. Primary outcomes analyzed included patient demographics and patient-related risk factors for PJIs following primary TSA. A stepwise backwards elimination multivariate binomial logistic regression analyses was performed to determine the odds (OR) of PJIs in patients undergoing primary TSA. A P value less than .05 was considered statistically significant.ResultsThe query yielded 15,396 patients who underwent primary TSA for glenohumeral OA, of which 191 patients developed PJIs and 15,205 did not develop PJIs. The study found statistically significant differences amongst patients who did and did not develop PJIs following primary TSA with respect to age, sex, and presence of comorbid conditions. Risk factors associated with developing PJIs following primary TSA included: pathologic weight loss (OR: 2.06, P < .0001), obesity (OR: 1.56, P = .0001), male sex (OR: 1.52, P = .007), and peripheral vascular disease (OR: 1.46, P = .022).ConclusionAs the number of primary TSAs for the treatment of glenohumeral OA increase worldwide, identifying modifiable risk-factors to reduce the incidence of infection is critical. The study found various modifiable and non-modifiable risk factors associated with developing PJIs following primary TSA. This study is valuable to orthopedists in order to identify and risk-stratify patients with regard to PJI in the setting of primary TSA for OA.Level of EvidenceLevel III; Case-Control Study 相似文献